Here we are Now, Enable us | Predictions for 2025
Michael Poku, M.D., chief clinical officer of Equality Health, shared his prediction for 2025.
Payers are increasingly recognizing the transformative potential of value-based care enablers. In 2025, payers will actively collaborate with these specialized organizations like never before to strengthen connections with providers, particularly independent primary care practices, and streamline activities critical to value-based care success. This will involve a strong focus on promoting member-centered care and services.
Poku
Expect to see more value-based care enablers entering the market, each offering innovative models designed to support providers in diverse ways. These models will range from reducing administrative burdens and standardizing payer relationships to simplifying quality metric reporting and leveraging technologies for proactive clinical workflows and preventive care.
Such partnerships will offload and downstream enablement from payer organizations, which will be essential for scaling value-based care, moving away from fee-for-service and achieving measurable improvements in health outcomes and cost reduction.
The Global Impact of Underfunding Women’s Health
February 20th 2025Bias and stigma are to blame for the way women’s health research has fallen behind, according to Monica Christmas, M.D., director of UChicago Medicine’s menopause program and the Center for Women's Integrated Health and Valentina Sartori, Ph.D., the leader of the McKinsey Health Institute's Life Sciences Practice in Europe.
Read More
Breaking Down Health Plans, HSAs, AI With Paul Fronstin of EBRI
November 19th 2024Featured in this latest episode of Tuning In to the C-Suite podcast is Paul Fronstin, director of health benefits research at EBRI, who shed light on the evolving landscape of health benefits with editors of Managed Healthcare Executive.
Listen
In this latest episode of Tuning In to the C-Suite podcast, Briana Contreras, an editor with MHE had the pleasure of meeting Loren McCaghy, director of consulting, health and consumer engagement and product insight at Accenture, to discuss the organization's latest report on U.S. consumers switching healthcare providers and insurance payers.
Listen
Solid Biosciences Reports Positive Data from DMD Gene Therapy Trial
February 19th 2025Solid Biosciences’ gene therapy uses a shortened version of the dystrophin protein, which is engineered to mimic the key functions of full-length dystrophin and allows it be delivered more effectively to muscle cells.
Read More
